SETH SANDESH 4
4 · Actinium Pharmaceuticals, Inc. · Filed Apr 2, 2025
Insider Transaction Report
Form 4
SETH SANDESH
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2025-03-31−25,000→ 0 totalExercise: $41.70Exp: 2027-03-14→ Common Stock (25,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-03-31−33,333→ 0 totalExercise: $23.49Exp: 2028-07-13→ Common Stock (33,333 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-03-31−310,182→ 0 totalExercise: $6.07Exp: 2031-09-01→ Common Stock (310,182 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-03-31−50,000→ 0 totalExercise: $6.96Exp: 2029-07-12→ Common Stock (50,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-03-31−16,666→ 0 totalExercise: $59.70Exp: 2026-04-15→ Common Stock (16,666 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-03-31−139,062→ 0 totalExercise: $9.55Exp: 2030-08-12→ Common Stock (139,062 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-03-31−827,366→ 0 totalExercise: $4.96Exp: 2032-07-01→ Common Stock (827,366 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-03-31−984,367→ 0 totalExercise: $5.00Exp: 2033-12-28→ Common Stock (984,367 underlying)
Footnotes (1)
- [F1]Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration.